Skip to main content
PMC home page
Applied Microbiology logoLink to Applied Microbiology
. 1965 Mar;13(2):212–215. doi: 10.1128/am.13.2.212-215.1965

Comparative In Vitro Activities of Lysostaphin and Other Antistaphylococcal Antibiotics on Clinical Isolates of Staphylococcus aureus

Edward F Harrison 1, C Bruce Cropp 1
PMCID: PMC1058223  PMID: 14325881

Abstract

The in vitro activity of lysostaphin against clinical isolates of Staphylococcus aureus was determined by conventional tube-dilution methods. For comparison, minimal inhibitory concentration (MIC) values were also determined for penicillin G, ampicillin, methicillin, ristocetin, vancomycin, and erythromycin. Phage type and penicillinase and coagulase production were determined for each isolate. The MIC values for lysostaphin ranged from <0.047 to 12.5 μg/ml; 96% of the penicillinase-positive strains were inhibited by 1.56 μg/ml of lysostaphin, whereas 3.12 μg/ml of vancomycin and methicillin were required to attain the same degree of inhibition.

Full text

PDF
212

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLAIR J. E., CARR M. The techniques and interpretation of phage typing of staphylococci. J Lab Clin Med. 1960 Apr;55:650–662. [PubMed] [Google Scholar]
  2. BROWN D. M., ACRED P. Chemotherapeutic studies on a new antibiotic-BRL.1241. Lancet. 1960 Sep 10;2(7150):568–569. doi: 10.1016/s0140-6736(60)91643-3. [DOI] [PubMed] [Google Scholar]
  3. CROPP C. B., HARRISON E. F. THE IN VITRO EFFECT OF LYSOSTAPHIN ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS. Can J Microbiol. 1964 Dec;10:823–828. doi: 10.1139/m64-107. [DOI] [PubMed] [Google Scholar]
  4. GRUNDY W. E., SINCLAIR A. C., THERIAULT R. J., GOLDSTEIN A. W., RICKHER C. J., WARREN H. B., Jr, OLIVER T. J., SYLVESTER J. C. Ristocetin, microbiologic properties. Antibiot Annu. 1956:687–692. [PubMed] [Google Scholar]
  5. HAIGHT T. H., FINLAND M. Modified Gots test for penicillinase production. Am J Clin Pathol. 1952 Aug;22(8):806–808. doi: 10.1093/ajcp/22.8_ts.806. [DOI] [PubMed] [Google Scholar]
  6. KJELLANDER J. O., KLEIN J. O., FINLAND M. IN VITRO ACTIVITY OF PENICILLINS AGAINST STAPHYLOCOCCUS ALBUS. Proc Soc Exp Biol Med. 1963 Aug-Sep;113:1023–1031. doi: 10.3181/00379727-113-28563. [DOI] [PubMed] [Google Scholar]
  7. KLEIN J. O., FINLAND M. THE NEW PENICILLINS. N Engl J Med. 1963 Nov 14;269:1074–CONTD. doi: 10.1056/NEJM196311142692006. [DOI] [PubMed] [Google Scholar]
  10. REEDY R. J., SHAFFER C. H., Jr In vitro sensitivity of bacteria to novobiocin, bryamycin, oleandomycin, vancomycin, amphomycin, bacitracin, and synnematin B. Antibiot Annu. 1956:483–485. [PubMed] [Google Scholar]
  11. SCHINDLER C. A., SCHUHARDT V. T. LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS. Proc Natl Acad Sci U S A. 1964 Mar;51:414–421. doi: 10.1073/pnas.51.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. WHITE A., VARGA D. T. Antistaphylococcal activity of sodium methicillin: 2,6-dimethoxyphenyl penicillin; penicillin X-1497. Arch Intern Med. 1961 Nov;108:671–678. doi: 10.1001/archinte.1961.03620110011003. [DOI] [PubMed] [Google Scholar]
  13. WISE R. I., VOIGT A. E., COLLIN M. V., CRANNY C. L. Origin of erythromycin-resistant strains of Micrococcus pyogenes in infections; bacteriophage types and in vitro resistance of cultures to antibiotics. AMA Arch Intern Med. 1955 Mar;95(3):419–426. doi: 10.1001/archinte.1955.00250090057008. [DOI] [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES